

## Special Issue

# Vaccination of Patients with Immune-Mediated Diseases

### Message from the Guest Editors

Patients with immune-mediated diseases are at increased risk of developing infections, due to disease-related immune dysfunction and applying of immunosuppressive drugs. Additional factors of increased infection risk include disease activity, malnutrition, surgical interventions, and concomitant chronic diseases, such as obesity, diabetes mellitus, atopic dermatitis, asthma, and others. Biologic therapy with and without immune suppressors can reliably control inflammatory activity in many patients with immune-mediated diseases. Infections are the most common complications associated with biological treatment and immune suppressors. Vaccination is a well-known and effective tool, which allows for reducing the frequency and severity of infectious episodes, and indirectly might reduce the risks of disease flare and failure to achieve remission, and significantly improve disease course and outcomes. This research topic is devoted to theoretical and practical experience of vaccinations of immune mediated pediatric and adult diseases.

---

### Guest Editors

Prof. Dr. Mikhail Kostik

Prof. Dr. James Galloway

Dr. Dimitri Poddighe

---

### Deadline for manuscript submissions

closed (20 September 2024)



## Vaccines

---

an Open Access Journal  
by MDPI

---

**Impact Factor 3.4**  
**CiteScore 9.9**  
**Indexed in PubMed**



[mdpi.com/si/162811](https://mdpi.com/si/162811)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).